VolitionRX (NYSEAMERICAN:VNRX) Receives “Hold” Rating from D. Boral Capital

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “hold” rating reissued by equities research analysts at D. Boral Capital in a report issued on Monday,Benzinga reports.

Several other brokerages have also issued reports on VNRX. HC Wainwright decreased their target price on VolitionRX from $1.50 to $1.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Citigroup lowered VolitionRX to a “hold” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $2.33.

VolitionRX Stock Performance

Shares of NYSEAMERICAN:VNRX opened at $0.18 on Monday. The stock’s fifty day simple moving average is $0.20 and its two-hundred day simple moving average is $0.29. VolitionRX has a 1-year low of $0.15 and a 1-year high of $0.94. The stock has a market cap of $28.34 million, a PE ratio of -0.81 and a beta of 1.33.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.71 million. On average, sell-side analysts forecast that VolitionRX will post -0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VolitionRX

Several large investors have recently added to or reduced their stakes in VNRX. Northwestern Mutual Wealth Management Co. purchased a new stake in VolitionRX in the 2nd quarter worth about $52,000. Virtu Financial LLC purchased a new stake in VolitionRX in the 3rd quarter worth about $28,000. Citadel Advisors LLC increased its holdings in VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after acquiring an additional 135,775 shares during the last quarter. Lagoda Investment Management L.P. increased its holdings in VolitionRX by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after acquiring an additional 782,000 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.